Chordate Medical

"During the first days, we have generated an impressive number of leads from stakeholders who clearly indicate buying interest. Awareness of Ozilia is beginning to establish itself at very satisfactory levels. We cannot currently serve all interested stakeholders since some markets outside the EU and GCC require product registration – but the need for Ozilia as a drug-free treatment alternative for migraine is evident," says Anders Weilandt.

Chordate is in Barcelona together with the company's Italian distributor Vedise Hospital S.p.A, who will bring home a number of leads. EHC is one of the foremost meeting places for the headache and migraine sector, with representatives from both research and industry from around the world.

"In addition to significant interest from the healthcare sector, we also notice that the exploratory interest from the pharmaceutical industry has increased significantly compared to previous congresses where we have participated. It is evident that they both want to learn more and understand what we are doing."